epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

ACAAI 2026

Insurers denied four in ten pediatric allergy biologic scripts

November 13, 2026

card-image

Clinical takeaway: When referring a child for a biologic, tell families coverage can take about a month and that a refusal is common. If a request is denied, the allergist can appeal or ask for a peer-to-peer review when available. 

For a child whose asthma, eczema, hives, or food allergy stays uncontrolled, an allergist may turn to a biologic, and the insurer usually has to approve it first. Each request can stall or end in a no. This analysis measures how often requests were turned down and how long approval took. 

Insurers denied 39.3% of the biologic prescriptions that required prior authorization, and 93.6% of the 326 prescriptions did. Each of two reasons accounted for about one in four denials: the child didn't meet the criteria, or the insurer wanted a different drug tried first. 

Approval took more than one month, or 32.65 days, on average from the day the allergist wrote the prescription. 

This retrospective chart review covered 326 biologic prescriptions written by allergists at one tertiary pediatric center from 2018 to 2026. Patients had a median age of 11.4 years, and 50.3% were male and 49.7% female. Omalizumab accounted for 55.8% of prescriptions and dupilumab for 26%. The rest were mepolizumab, benralizumab, and tezepelumab. 

The researchers suggest the need for changes to the prior authorization process so families can get the medicines their doctors prescribe without long waits. 

"When a child's asthma or allergies are out of control, every week counts," said allergist Aarti Pandya, MD, co-author of the study. "The doctor and the family have already decided this medication is the right choice. Then they wait, sometimes for more than a month, and many times the answer is still no. Delays like these can put children at risk of serious health problems." 

Source: Holland M, et al. (2026 Nov 12) American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting. Abstract R301. Biologic Medication Denials in Pediatric Atopic Conditions

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information